药物经济学在我国药品定价中应用的定位分析

目的为药物经济学在我国药品定价中的正确应用提供政策建议。方法通过介绍我国药品价格管制措施的局限性,探讨药物经济学在药品定价中应用的可行性及必要性,进一步分析药物经济学在药品定价中应用所需的明确定位。结果与结论在药品定价中药物经济学所评价的药物范围应为新药和专利期内的垄断药品。作为应用主体的定价部门应站在全社会角度通过制定权威的药物经济学评价指南,委托第三方专家组对制药企业提交的药物经济学评价报告进行评估,将评估结果作为药品定价部门与制药企业谈判协商价格时的科学依据,在达到对新药和专利期内垄断药品控费的同时,鼓励药品创新和研发,最终保证患者对药品持续的可及性。

Positioning Analysis of Application of Pharmacoeconomics in Drug Pricing in China

Objective To provide policy recommendations for the correct application of pharmacoeconomics in drug pricing in China.Methods By introducing the limitations of drug price regulated measures,we discuss the feasibility and necessity of application of pharmacoeconomics in drug pricing,and further analyze the explicit positioning of application of pharmacoeconomics in drug pricing.Results and Conclusions The scope of pharmacoeconomics evaluation in drug pricing should include only new and patented drugs.As the subject of application,the pricing department should make authoritative guidelines for pharmacoeconomics evaluation from the perspective of whole society,and entrust third-party expert group to evaluate reports submitted by pharmaceutical companies.Based on the evaluated results above,drug pricing department could negotiate the price with pharmaceutical companies,which could control fees that are caused by monopoly of new and patented drugs.Then it will encourage pharmaceutical innovation and RD and ensure persistent availability of drugs for patients.